Aspirin and coronary artery disease

Summary

Coronary atherosclerosis (CAD), a chronic inflammatory disorder, arises when genetic susceptibility, intercurrent conditions such as diabetes and hypertension and environmental factors interact. Although CAD can remain stable for many years, thrombus formation at sites of plaque rupture may lead to unstable angina (UA) or myocardial infarction (MI). Already recognised as the central component of coronary thrombosis, platelets, through their interaction with monocytes and endothelial cells, may also be involved at the earliest stages of atheromatous plaque evolution. Aspirin, the prototype antiplatelet agent, covalently and irreversibly inhibits cyclooxygenase (COX) and thus inhibits platelet thromboxane (TX) A2 biosynthesis. Anti-oxidant properties and the ability to modulate transcription of immunologically important genes have also been attributed to aspirin. Non-selective COX inhibition, however, predisposes to bleeding, predominantly secondary to dosedependent gastro-intestinal toxicity. The emerging concept of “aspirin resistance” coincides with the development of alternative antiplatelet therapy and point-of-care platelet function assays. Though variable aspirin pharmacokinetics may explain many cases, heritable factors, inducible platelet COX expression and isoprostane formation may also contribute. In future, risk factor screening and point-of-care platelet function assay may identify vulnerable patients who would benefit from additional or alternate antiplatelet therapy.

Keywords

Atherosclerosis - coronary thrombosis - antiplatelet - aspirin resistance - heritable

• References

• 1 Moers A, Nieswandt B, Massberg S. et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 2003; 09: 1418-22.
• 2 Maree A, Fitzgerald D. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: Where are we now?. Semin Vasc Med 2003; 03: 385-90.
• 3 Xie WL, Chipman JG, Robertson DL. et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991; 88: 2692-6.
• 4 Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
• 5 Kurumbail RG, Stevens AM, Gierse JK. et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-8.
• 6 Chandrasekharan NV, Dai H, Roos KL. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 13926-31.
• 7 Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956; 78: 213-5.
• 8 Elwood PC, Cochrane AL, Burr ML. et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1974; 01: 436-40.
• 9 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
• 10 Patrono C, Bachmann F, Baigent C. et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25: 166-81.
• 11 Smith Jr. SC, Blair SN, Bonow RO. et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104: 1577-9.
• 12 Lecomte M, Laneuville O, Ji C. et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994; 269: 13207-15.
• 13 Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.
• 14 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72.
• 15 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-32.
• 16 Fitzgerald DJ, Roy L, Catella F. et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-9.
• 17 Peto R, Gray R, Collins R. et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-6.
• 18 Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321: 129-35.
• 19 Manson JE, Stampfer MJ, Colditz GA. et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. Jama 1991; 266: 521-7.
• 20 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351: 233-41.
• 21 Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
• 22 de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
• 23 Nurden A. Human Platelet Glycoproteins. In: Bloom AFCD. Haemostasis and Thrombosis. New York: Churchill Livingstone; 1994: 115-65.
• 24 Weyrich AS, Elstad MR, McEver RP. et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-34.
• 25 Amirkhosravi A, Alexander M, May K. et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87-95.
• 26 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 27 Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-8.
• 28 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
• 29 Coppinger JA, Cagney G, Toomey S. et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104.
• 30 von Hundelshausen P, Weber KS, Huo Y. et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-7.
• 31 Ridker PM, Cushman M, Stampfer MJ. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
• 32 Patrono C, Coller B, Dalen JE. et al. Plateletactive drugs : the relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63S.
• 33 Steer KA, Wallace TM, Bolton CH. et al. Aspirin protects low density lipoprotein from oxidative modification. Heart 1997; 77: 333-7.
• 34 Husain S, Andrews NP, Mulcahy D. et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97: 716-20.
• 35 Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-9.
• 36 Saunders MA, Sansores-Garcia L, Gilroy DW. et al. Selective suppression of CCAAT/ enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem 2001; 276: 18897-904.
• 37 Cianferoni A, Schroeder JT, Kim J. et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001; 97: 1742-9.
• 38 Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 05: 138-46.
• 39 Chang ET, Zheng T, Weir EG. et al. Aspirin and the risk of Hodgkin’s lymphoma in a population-based case-control study. J Natl Cancer Inst 2004; 96: 305-15.
• 40 Kinoshita T, Takahashi Y, Sakashita T. et al. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999; 1438: 120-30.
• 41 United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed) 1988; 296: 316-20.
• 42 Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345-9.
• 43 Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7.
• 44 Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1-12.
• 45 Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?. Pharmacotherapy 1998; 18: 1041-52.
• 46 Tamminen M, Lassila R, Westerbacka J. et al. Obesity is associated with impaired plateletinhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003; 27: 907-11.
• 47 Alexander JH, Harrington RA, Tuttle RH. et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999; 83: 1147-51.
• 48 Santos MT, Valles J, Aznar J. et al. Pro-thrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 1997; 95: 63-8.
• 49 Wang JC, Aucoin-Barry D, Manuelian D. et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92: 1492-4.
• 50 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
• 51 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
• 52 Serebruany V, Malinin A, Sane D. et al. The AGgrenox versus Aspirin Treatment Evaluation (AGATE) for platelet inhibition after stroke. Circulation. 2003 108. (Suppl IV): IV-602 (Abstract 2736).
• 53 Cerletti C, Dell’Elba G, Manarini S. et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003; 42: 1059-70.
• 54 Alberts MJ, Bergman DL, Molner E. et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175-8.
• 55 de Gaetano G, Cerletti C, Dejana E. et al. Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction. Circulation 1985; 72: 1185-93.
• 56 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
• 57 Zimmermann N, Wenk A, Kim U. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
• 58 Cayatte AJ, Du Y, Oliver-Krasinski J. et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 1724-8.
• 59 Cipollone F, Ciabattoni G, Patrignani P. et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 1007-13.
• 60 Roncaglioni MC, Santoro L, D’Avanzo B. et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation 1992; 85: 2065-72.
• 61 O’Donnell CJ, Larson MG, Feng D. et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103: 3051-6.
• 62 Kurrelmeyer K, Becker L, Becker D. et al. Platelet hyperreactivity in women from families with premature atherosclerosis. J Am Med Womens Assoc 2003; 58: 272-7.
• 63 Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med (Maywood) 2001; 226: 409-19.
• 64 Macchi L, Christiaens L, Brabant S. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-9.
• 65 Kawasaki T, Ozeki Y, Igawa T. et al. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 591-5.
• 66 Naber C, Hermann BL, Vietzke D. et al. Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele. FEBS Lett 2000; 484: 199-201.
• 67 O’Connor FF, Shields DC, Fitzgerald A. et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 3256-60.
• 68 Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-30.
• 69 Ulrich CM, Bigler J, Sibert J. et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002; 20: 409-10.
• 70 Maree A, Curtin R, Dooley M. et al. Potential role of a COX-1 polymorphism in aspirin resistance. Blood. 2003 102. Abstract.